Clinical Trial Detail

NCT ID NCT02309177
Title Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Celgene Corporation
Indications

lung non-small cell carcinoma

Her2-receptor negative breast cancer

pancreatic adenocarcinoma

Therapies

Carboplatin

Gemcitabine

Nab-paclitaxel + Nivolumab

Age Groups: adult

Additional content available in CKB BOOST